Joseph Scheeren, PharmD, is President and Chief Executive Officer of Critical Path Institute, an Arizona based nonprofit (501(c)(3)). Scheeren leads the Institute in its mission to catalyze the development of new tools to advance medical product innovation and regulatory science. C-Path establishes and leads teams that share data, knowledge and expertise resulting in sound, consensus-based science. Scheeren assumed the role of President and CEO in April 2019. He previously served as Senior Advisor Research and Development for Bayer AG.
Scheeren has had a distinguished 36-year career in the pharmaceutical industry having held positions domestically and internationally in drug development and regulatory approval on three continents. He has in-depth knowledge and leadership experience with drug development and the regulatory process which is evidenced by a long list of first cycle approvals for new therapies he has been directly involved in.
Scheeren joined Bayer Pharmaceuticals as Senior Vice President, Head of Global Regulatory Affairs, in 2004, responsible for development in the US and in 2009 became Site Head US in Montville, NJ. In 2012, he assumed the position of Head of Global Development Asia in Beijing and in 2015, was appointed Head of Global Regulatory Affairs Pharma and Consumer Care of Bayer Healthcare, Basel, Switzerland. In January 2018, he was appointed Senior Advisor R&D, Bayer AG. Scheeren’s experience with global regulatory affairs will help C-Path expand its mission worldwide.
He has an established network of connections across the globe and holds many memberships and designations. He serves on the advisory boards at the Center for Innovation in Regulatory Science, the Center of Regulatory Excellence Singapore, the Research & Development-based Pharmaceutical Association in China, and the China Core Research and Development Committee. He is currently serving as Board chair of the Drug Information Association (DIA) and has served as Chairman of the DIA Regional Advisory Council for Europe, the Middle East and Africa; he is also a foreign member of the Academie Nationale de Pharmacie, France, a lecturer at Yale University and an adjunct Professor at Peking University.
Mary Teeling is a specialist pharmaceutical physician with over 30 years’ experience in the areas of pharmacology and pharmaceutical medicine. She developed the Master of Science (MSc) in Pharmaceutical Medicine in 2004, while working in Trinity College Dublin, and was course director up until 2018. As assistant professor in the School of Medicine in Trinity College Dublin, her main research interest was in the area of pharmacoepidemiology, including prescribing patterns, influences on prescribing, quality indicators, rational prescribing, and pharmacovigilance. Currently, she is adjunct professor of pharmaceutical medicine within the department of Pharmacology and Therapeutics.
She also worked as a part-time medical advisor to the National Medicines Information Centre (NMIC) for 17 years up until 2018, where her role involved writing therapeutics bulletins and newsletters for healthcare professionals and providing education on safe prescribing for doctors in training. Prior to working in Trinity College Dublin and NMIC, she worked in the Irish Medicines Board (now Health Products Regulatory Authority) for 12 years and was its medical director for six years. She was the Irish member of the EU Committee for Human Medicinal Products (CHMP) and served as its vice-chair for three years.
Teeling was part of the educational team that developed the higher speciality training (HST) programme in pharmaceutical medicine with the Royal College of Physicians in Ireland, which achieved approval from the Medical Council of Ireland in 2016. She is the current national specialty director (NSD) for the programme. She is a member of the NDA Regulatory Advisory Board, which is composed of other former EU regulatory and industry experts (www.ndareg.com). She is an honorary consultant for the review panel of the WHO Uppsala Monitoring Centre (UMC) involved in safety signal identification.
Caitriona O’Driscoll is a Pharmacist, and Professor and Chair of Pharmaceutics in the School of Pharmacy in University College Cork (UCC). She completed her PhD studies in Pharmaceutical Sciences in Trinity College Dublin (TCD) and undertook a sabbatical in the Department of Pharmaceutical Chemistry at the University of Kansas, USA. She was a senior lecturer in the School of Pharmacy at TCD prior to her appointment to UCC in 2003. She is a Board member of the Irish Health Products Regulatory Authority and is a founding member and Chair of Regulatory Science Ireland.
Professor O’Driscoll’s research strategy is translational in nature and product driven. The research is focused on the design, formulation and characterisation of biomimetic drug delivery systems incorporating the products of the pharmaceutical biotechnology industry such as peptide/protein type drugs and nucleic acids. To accelerate translation into the clinic, nano-sized drug delivery constructs are engineered to maintain stability during processing and storage, and to ensure safe and effective use by patients.
John Hegarty has over 40 years of experience in research, education, and university leadership in Ireland and the US.
He was President/Provost of Trinity College Dublin from 2001 to 2011 at a time of significant transformation of research and organizational structure. He was Professor of Laser Physics at Trinity from 1986. Previously, he spent 10 years in the US carrying out research in photonics in Bell Labs NJ and the University of Wisconsin Madison. He has published about 130 peer-reviewed papers in photonics, and co-founded Eblana Photonics. He served on many national advisory committees. He has a PhD in Physics from the National University of Ireland Galway, a higher doctorate(DSc) from the University of Dublin, and honorary doctorates from University College Dublin, Queens University Belfast, and University of Ulster.
More recently, he co-founded Innovation Advisory Partners advising on education, research, and innovation policy. He is Chair of the Irish Times Trust and a member of the Irish Times Board. He is also a member of the Fulbright Ireland Board, the Hugh Lane Gallery Board, and chairs the Translation Medicine Institute based in St James’s Hospital.
Enda Connolly has held leadership roles in Economic Development, Science, and Innovation in Ireland for over 35 years.
As Chief Executive of the Health Research Board, he led a team of seventy skilled professionals implementing a new business strategy that repositioned Irish health research by introducing innovative funding initiatives which place the emphasis on patient-orientated research and its application into practice.
Previously, as a member of the Executive Team of IDA Ireland, he played a lead role in the development and implementation of three successful corporate strategies. Senior Management responsibilities at IDA included: Manager of Research Strategy, devising and implementing IDA’s strategy to attract R&D investment from multi-national corporations; Director North America, based in the US, delivering 250 new investments valued at over €5bn; Manager, International Services, developing the Services Business Sector as an emerging long-term strategic economic opportunity.
Most recently, Enda has worked as a strategic advisor on economic development projects for the governments of Qatar and Saudi Arabia.
Currently, he is Chairman of the Board of Beaumont Hospital, a Member of the Board of the RCSI Hospital Group, as well as a Member of the Board of the Health Information and Quality Authority.